CRBPHealthcare · BiotechnologyThe 10 Wall Street analysts covering Corbus Pharmaceuticals Holdings, Inc. hold a median 12-month price target of $35 — +729.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 28 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Corbus Pharmaceuticals Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (76): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (13): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CRBP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +729.4% from it.
Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $35 |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $40 → $35 |
| 7 Aug 2026 | Oppenheimer | Maintains | Outperform | — |
| 7 Aug 2026 | Oppenheimer | Maintains | Outperform | $52 → $48 |
| 23 June 2026 | Mizuho | Maintains | Outperform | $44 → $34 |
| 23 June 2026 | Mizuho | Maintains | Outperform | — |
| 17 June 2026 | Oppenheimer | Maintains | Outperform | $54 → $52 |
| 17 June 2026 | Oppenheimer | Maintains | Outperform | — |
| 27 May 2026 | Wedbush | Maintains | Outperform | — |
| 26 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 May 2026 | Mizuho | Maintains | Outperform | — |
| 13 May 2026 | Guggenheim | Reiterates | Buy | — |
| 13 May 2026 | Jefferies | Maintains | Buy | — |
| 13 May 2026 | Oppenheimer | Maintains | Outperform | — |
| 29 Apr 2026 | Guggenheim | Initiates | Buy | — |
| 10 Mar 2026 | Oppenheimer | Maintains | Outperform | — |
| 13 Nov 2025 | RBC Capital | Maintains | Outperform | — |
| 20 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Oct 2025 | Wedbush | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CRBP appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Corbus Pharmaceuticals Holdings, Inc. returned −75.0% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 77% of US stocks
Cheaper than 60% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 14% of US stocks
Higher than 7% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Corbus Pharmaceuticals Holdings, Inc. has a market value of $80.3M and an enterprise value of −$33.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$101.9M.
Diluted earnings per share, trailing twelve months: $−6.19.
Free cash flow in the twelve months to 30 June 2026: −$86.7M.
Trailing P/E: −0.7×; forward P/E: −0.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Corbus Pharmaceuticals Holdings, Inc. employs 36 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Corbus Pharmaceuticals Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Corbus Pharmaceuticals announced that late-breaking data from its CRB-913 Canyon-1 Phase 1B study will be presented as a poster at Obesity Week 2026, scheduled for November 14–17 in National Harbor, Maryland.
Why it matters — The presentation will provide an opportunity for CRBP watchers to learn about data from the company’s CRB-913 obesity study.
Corbus Pharmaceuticals announced that the first patient has been dosed in its TEMPO-1 registrational study of CRB-701, a next-generation Nectin-4 targeted antibody drug conjugate, in second-line and beyond oropharyngeal squamous cell carcinoma. The company noted that OPSCC incidence and prevalence are rising in the U.S., largely driven by HPV infection, with an estimated 14,000 patients eligible for treatment annually.
Why it matters — This milestone advances CRB-701 into a registrational study targeting a growing patient population in oropharyngeal cancer, a key clinical development step for CRBP's pipeline.
Zacks reports that Corbus Pharmaceuticals announced positive obesity study data, which boosts the company's cannabinoid-based strategy. The report also highlights CRB-701 and the company's cash needs as additional factors for investors to consider.
Why it matters — CRBP watchers would care because the positive obesity data supports the company's core cannabinoid strategy, while the status of CRB-701 and its cash position add important context to its outlook.
Corbus Pharmaceuticals reported top-line results from CANYON-1, a Phase 1b placebo-controlled trial of CRB-913, an oral CB1 inverse agonist for obesity. The 12-week study enrolled 254 patients with an average BMI of approximately 37 across 15 U.S. sites.
Why it matters — The findings provide an early readout on the safety and efficacy of CRB-913, a key candidate in Corbus' obesity pipeline.
The item is a transcript of a Seeking Alpha call discussing Corbus Pharmaceuticals Holdings, Inc.'s Phase 1b topline results for CRB-913 in obesity and its potential as a weight loss therapy. It covers the presentation of these trial results and the compound's outlook.
Why it matters — CRBP watchers would care because the transcript details clinical data and developments for CRB-913, a key pipeline candidate in the obesity space.
The 10 Wall Street analysts covering Corbus Pharmaceuticals Holdings, Inc. have a median 12-month price target of $35, with estimates ranging from $28 to $48. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Corbus Pharmaceuticals Holdings, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Corbus Pharmaceuticals Holdings, Inc. 18 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Corbus Pharmaceuticals Holdings, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (76 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +729.4% from the last close, and Ticker Nerd's factor model ranks Corbus Pharmaceuticals Holdings, Inc. 18 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Corbus Pharmaceuticals Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRBP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $48 over the next 12 months.
Corbus Pharmaceuticals Holdings, Inc. returned -75.0% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and obesity.
The most recent item we track (GlobeNewsWire, 22 Oct 2026): "Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026". Corbus Pharmaceuticals announced that late-breaking data from its CRB-913 Canyon-1 Phase 1B study will be presented as a poster at Obesity Week 2026, scheduled for November 14–17 in National Harbor, Maryland.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and obesity. Corbus Pharmaceuticals Holdings, Inc. advances a pipeline centered on targeted treatments, including CRB-701, an antibody drug conjugate designed to target Nectin-4 on cancer cells, and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist being studied for obesity. The company’s work is concentrated on well-defined biological pathways and on creating medicines that address serious diseases through precision-focused mechanisms. Corbus Pharmaceuticals Holdings, Inc. plays a role in the biotechnology market as a developer of investigational drug candidates aimed at cancer and metabolic disease, with its current programs spanning clinical research and product development in these therapeutic areas.
CEO Dr. Yuval Cohen Ph.D. · 36 employees · United States · https://www.corbuspharma.com
